NOS1 and diabetes mellitus: In the present study, we report for the first time that CB2R activation by the selective agonist AM1710, administered topically as eye drops for two weeks, was able to block the diabetes-induced loss of a subpopulation of amacrine cells [nitric oxide synthetase (NOS) expressing].